Prevention and control of risk factors in metabolic and alcohol-associated steatotic liver disease

Simple item page
dc.coverageDOI: 10.20517/mtod.2024.30
dc.creatorDesalegn, Hailemichael
dc.creatorFarias, Renata
dc.creatorHudson, David
dc.creatorIdalsoaga, Francisco
dc.creatorCabrera, Daniel
dc.creatorDiaz, Luis Antonio
dc.creatorArab, Juan Pablo
dc.date2024
dc.date.accessioned2025-11-18T19:55:26Z
dc.date.available2025-11-18T19:55:26Z
dc.description<p>Steatotic liver disease (SLD), including metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD), is the primary cause of illness and mortality. In particular, MASLD affects more than 30% of the global population, while ALD accounts for 5.1% of all diseases and injuries worldwide. The SLD spectrum includes a variety of clinical conditions, from mild fatty liver and inflammation to different stages of liver fibrosis. Additionally, both conditions (MASLD and ALD) can be complicated by hepatocellular carcinoma (HCC), while around one-third of ALD patients can also develop at least one alcohol associated hepatitis (AH) episode. Both of these diseases are also associated with multiple extrahepatic complications, such as cardiovascular disease, chronic kidney disease, and malignancies. In MASLD, the rapid rise in global obesity and type 2 diabetes mellitus (T2DM) prevalence due to Westernized lifestyles has led to an increase in the prevalence of MASLD. Thus, the prevention and control of cardiometabolic risk factors (CMRFs) are the cornerstone of its treatment. Hypertension and atherogenic dyslipidemia are also important CMRFs associated with MASLD. Susceptible individuals with MASLD are adversely affected by even a small amount of alcohol consumption (though there is no agreed definition of a small amount), increasing the risk of severe outcomes and a faster progression of liver disease. This review explores factors that play a role in the development of SLD, especially focusing on the management of CMRFs and levels of alcohol use to prevent liver disease progression.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/37dcec2f-e18d-4f37-9d9f-3819405edb10
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/59263
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.4 (2024) nr.3
dc.subjectAlcohol
dc.subjectalcohol use disorder
dc.subjectalcohol-associated liver disease
dc.subjectalcohol-associated liver disease (ALD)
dc.subjectmetabolic dysfunction-associated steatotic liver disease
dc.subjectSDG 3 - Good Health and Well-being
dc.titlePrevention and control of risk factors in metabolic and alcohol-associated steatotic liver diseaseeng
dc.typeReview articleeng
dc.typeArtículo de revisiónspa
Files
Collections
PURE